Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.35), $0.03 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $13.48 million versus the consensus estimate of $13.2 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.